In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche CEO Severin Schwan: Fueled By Innovation, Emerging Markets

Executive Summary

Roche’s CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.

You may also be interested in...



Real World Data Solutions For Pharma’s Looming EBIT Crisis

The global pharmaceutical industry is facing decreasing margins triggered by various internal and external reasons. To address the crisis effectively long term, we see pharma’s integration into care management, combined with data generation and analysis of real-world outcomes, as a way to charge for the value pharma adds.

Roche Follow-On Development Strategy Highlighted By Strong 1H Results

Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.

Isis Teams Up With Roche In Early-Stage Huntington’s Deal

The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel